IDiyas

For the Inventor, By the Inventor

Al-Ahsa, Saudi Arabia

Nagaraja Sreeharsha

USPTO Granted Patents = 15

Average Co-Inventor Count = 11.3

ph-index = 2

Forward Citations = 4(Granted Patents)


Location History:

  • Hofouf, SA (2022)
  • Al-Ahsa, SA (2023 - 2024)

Company Filing History:

goldMedal15 out of 3,201 
 
King Fahd University of Petroleum and Minerals
 patents

Years Active: 2022-2025

Loading Chart...
15 patents (USPTO):Explore Patents
1. 12297204 - 5-(substitutedphenyl)-7-thioxo-7,8-dihydropyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione analogues as antibacterial agents (2025-05-13),
2. 12221450 - 5-(substitutedphenyl)-7-thioxo-7,8-dihydropyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione analogues as antibacterial agents (2025-02-11),
3. 12187733 - 5-(Substitutedphenyl)-7-Imino-7,8-Dihydropyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione analogues as anti-inflammatory agents (2025-01-07),
4. 11974991 - Adenosine receptor activity of methyl/ethyl 3-(substituted benzoyl)-6,8-dimethylindolizine-2-substituted-1-carboxylates (2024-05-07),
5. 11964982 - 5-(3-substituted phenyl)-pyrimido[4,5-d]pyrimidine-2,4,7(1H,3H,8H)-trione derivatives as anticancer agents (2024-04-23),
6. 11938120 - Ethyl 2-substituted-1-(substitutedbenzoyl)-7-methylpyrrolo[1,2-a]quinoline-3-carboxylate derivatives as anti-tubercular agents (2024-03-26),
7. 11932649 - 5-(3-substituted phenyl)-pyrimido[4,5-d]pyrimidine-2,4,7(1H,3H,8H)-trione derivatives as anticancer agents (2024-03-19),
8. 11926627 - Substituted 7-methyl quinoline derivatives as antitubercular agents (2024-03-12),
9. 11919900 - 1-substituted benzoyl-4-bromopyrrolo[1,2-a]quinoline-3-carboxylate derivatives as antitubercular agents (2024-03-05),
10. 11884677 - 5-(substitutedphenyl)-7-imino-7,8-dihydropyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione analogues as anti-inflammatory agents (2024-01-30),
11. 11884631 - Substituted phenyl quinolin-l-ium bromide derivative as anti-tubercular agents (2024-01-30),
12. 11845746 - Ethyl 2-substituted-1-(substitutedbenzoyl)-7-methylpyrrolo[1,2-a]quinoline-3-carboxylate derivatives as anti-tubercular agents (2023-12-19),
13. 11807640 - 7-isopropyl 1-ethyl/methyl 3-(substituted benzoyl)-2-substituted indolizine-1,7-dicarboxylates as anti-tubercular agents (2023-11-07),
14. 11807553 - Decontamination of water using guar gum derivatives and applications thereof (2023-11-07),
15. 11530217 - Antitubercular compounds (2022-12-20),

Title: Innovations of Nagaraja Sreeharsha in Antibacterial Agents

Introduction

Nagaraja Sreeharsha is a prominent inventor based in Al-Ahsa, Saudi Arabia. He has made significant contributions to the field of medicinal chemistry, particularly in the development of antibacterial agents. With a total of 15 patents to his name, Sreeharsha's work focuses on innovative compounds that address microbial and bacterial infections.

Latest Patents

Among his latest patents are the 5-(substitutedphenyl)-7-thioxo-7,8-dihydropyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione analogues. These compounds are designed as antibacterial agents, specifically targeting microbial and bacterial infections. The compounds are characterized by their unique formula and are intended for use as effective anti-microbial or anti-bacterial agents.

Career Highlights

Sreeharsha is affiliated with King Fahd University of Petroleum and Minerals, where he conducts research and development in the field of pharmaceuticals. His innovative approach to creating new compounds has garnered attention in the scientific community, contributing to advancements in antibacterial treatments.

Collaborations

He has collaborated with notable colleagues, including Katharigatta N Venugopala and Mahesh Attimarad. These partnerships have enhanced the research efforts and broadened the scope of their work in medicinal chemistry.

Conclusion

Nagaraja Sreeharsha's contributions to the field of antibacterial agents highlight his innovative spirit and dedication to addressing critical health challenges. His work continues to pave the way for new treatments in the fight against microbial infections.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…